List of Excipients in Branded Drug LINZESS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	LINZESS	linaclotide	0456-1201	CALCIUM CHLORIDE	2032-04-30
Allergan Inc	LINZESS	linaclotide	0456-1201	CELLULOSE, MICROCRYSTALLINE	2032-04-30
Allergan Inc	LINZESS	linaclotide	0456-1201	GELATIN	2032-04-30
Allergan Inc	LINZESS	linaclotide	0456-1201	HYPROMELLOSE	2032-04-30
Allergan Inc	LINZESS	linaclotide	0456-1201	LEUCINE	2032-04-30
Allergan Inc	LINZESS	linaclotide	0456-1201	TITANIUM DIOXIDE	2032-04-30

Linzess Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Linzess, the brand name for linaclotide, is a low-dose peptide drug whose commercial performance depends on more than active-ingredient synthesis. Excipient selection affects content uniformity, moisture protection, capsule performance, pediatric administration, stability, and generic bioequivalence. The largest opportunities are in hard-capsule systems, low-dose formulation technology, pediatric sprinkle delivery, moisture-control packaging, and manufacturing support for generic linaclotide.

Linzess has three U.S. capsule strengths: 72 mcg, 145 mcg, and 290 mcg. The FDA-approved product treats irritable bowel syndrome with constipation in adults, chronic idiopathic constipation in adults, and functional constipation in pediatric patients aged 6 to 17 years.[1]

What excipients are used in Linzess capsules?

Linzess capsules use a conventional solid oral dosage form with a highly potent, low-dose peptide payload. The FDA prescribing information identifies inactive ingredients that include gelatin, hypromellose, L-leucine, microcrystalline cellulose, titanium dioxide, and calcium chloride dihydrate, with colorants varying by capsule strength.[1]

Formulation element	Commercial function
Gelatin or hypromellose capsule shell	Encapsulation, dose handling, and product presentation
Microcrystalline cellulose	Diluent and carrier for low-dose drug loading
L-leucine	Powder-flow and formulation-performance aid
Calcium chloride dihydrate	Moisture and stability control in the drug product
Titanium dioxide and colorants	Capsule identification and branding
Blister or bottle packaging	Protection from moisture and handling exposure

The drug substance is present at microgram quantities. That creates a high excipient-to-active ratio and makes blend uniformity a primary manufacturing risk. A formulation can contain large quantities of excipient while still requiring tight controls over segregation, electrostatic behavior, powder flow, and assay variability.

Why does Linzess require a specialized excipient strategy?

Linzaclotide is a 14-amino-acid peptide. Its formulation strategy must preserve the active molecule during manufacture, storage, and gastrointestinal delivery while maintaining a reproducible dose at very low loading.

Low-dose content uniformity

A 72-mcg capsule creates the greatest content-uniformity challenge. The formulation must distribute a small quantity of peptide across a comparatively large powder mass. Particle-size matching, geometric dilution, controlled blending, and low-shear processing are central to commercial scale-up.

Excipient suppliers can compete by providing:

• Narrow particle-size distributions
• Low-moisture grades of microcrystalline cellulose
• Consistent bulk density
• Low-electrostatic powder systems
• Validated flow and blend-uniformity performance
• Excipient grades suitable for automated capsule filling

The commercial value is highest when the supplier provides formulation data and process compatibility rather than only a compendial material.

Moisture control

Peptide stability can be affected by water activity, hydrolysis, aggregation, and changes in the solid-state environment. Calcium chloride dihydrate and moisture-protective packaging must be considered together. A manufacturer changing the excipient system may need to establish equivalent stability performance through accelerated and long-term studies.

Moisture-control opportunities include:

• High-barrier blister films
• Desiccant-integrated bottles
• Low-permeability capsule shells
• Moisture-scavenging secondary packaging
• Humidity-controlled filling and storage
• Stability-indicating analytical methods

Packaging is commercially important because an apparently minor change in bottle, blister, liner, or closure system can alter the moisture profile of a low-dose peptide product.

What formulations are protected by Linzess patents?

Linzess patent protection has historically centered on linaclotide composition, pharmaceutical formulations, treatment methods, and manufacturing-related claims. The relevant commercial question for an excipient supplier is whether a proposed formulation or process creates a patent issue for the generic applicant, the branded manufacturer, or both.

Protection category	Relevance to excipient strategy
Linaclotide composition claims	Limits alternative active-ingredient approaches
Pharmaceutical composition claims	Can cover drug-excipient combinations or dosage forms
Method-of-use claims	Relevant to IBS-C, chronic constipation, and pediatric use
Manufacturing claims	May affect peptide synthesis, purification, drying, or blending
Pediatric administration claims	Can affect sprinkle-on-food or water-dispersion products
Stability and packaging claims	May constrain moisture-control systems

The core U.S. linaclotide patent estate has included U.S. Patent No. 7,304,036, assigned to Ironwood Pharmaceuticals and related parties. Public company filings have described additional U.S. patent protection extending beyond the core composition patent, including patents directed to formulations and uses.[2][3]

Excipient suppliers should distinguish between:

1. A material that is already used in the branded product.
2. A materially different excipient system used in an ANDA product.
3. A process aid that does not remain in the finished dosage form.
4. A packaging component that may be covered by separate claims.
5. A pediatric delivery system that creates new method or formulation exposure.

A supplier’s material may be commercially useful without being patent-distinctive. In that case, value comes from quality, supply reliability, and regulatory support rather than exclusivity.

When does Linzess lose exclusivity?

Linzess faces a staged loss-of-exclusivity profile rather than a single date. FDA regulatory exclusivity, Orange Book patents, pediatric exclusivity, litigation settlements, and commercial launch provisions can produce different effective entry dates.

Event	Commercial effect
Core patent expiry	Removes the principal composition barrier
Later formulation or use patent expiry	Can preserve narrower barriers
Pediatric exclusivity	May extend listed patent or regulatory protection
ANDA approval	Does not necessarily mean immediate commercial launch
Paragraph IV settlement	May establish a negotiated generic-entry date
Authorized generic launch	Can change price and channel dynamics before full generic entry

Ironwood and AbbVie have reported patent protection and settlement arrangements affecting future generic entry for linaclotide products.[2][3] Public filings have identified the mid-2020s as the period when core U.S. protection begins to weaken, with later protection potentially affecting specific formulations, indications, or launch timing.

The practical commercial window for excipient suppliers begins before legal exclusivity ends. Generic manufacturers typically qualify alternate suppliers, establish commercial-scale processes, and generate stability data well before launch. Supplier selection can therefore occur during the patent-protected period.

What is the FDA regulatory status of Linzess?

The FDA approved Linzess in 2012 for adults with IBS-C and in 2017 for adults with chronic idiopathic constipation. In 2023, FDA expanded the label to include functional constipation in pediatric patients aged 6 to 17 years at a 72-mcg once-daily dose.[1][4]

The pediatric approval creates a distinct excipient and administration opportunity. The product can be administered as an intact capsule or by opening the capsule and sprinkling the contents on applesauce, or mixing with water according to the prescribing information.[1]

Pediatric formulation implications

Pediatric use increases the importance of:

• Dispersion uniformity after capsule opening
• Adhesion of powder to food or dosing vessels
• Palatability and mouthfeel
• Administration-device compatibility
• Stability after temporary dispersion
• Clear instructions for caregivers
• Avoidance of crushing or inappropriate mixing conditions

A pediatric-friendly formulation that changes the excipient system may require new comparative quality data. The opportunity is strongest for excipients that improve powder recovery, reduce adherence to containers, and preserve dose uniformity during sprinkle administration.

How many patents cover Linzess?

The relevant Linzess estate includes multiple U.S. patents and patent families, but the count depends on whether the analysis includes expired patents, terminally disclaimed patents, formulation patents, method-of-use patents, and international rights. Commercial filings have described a portfolio extending beyond the foundational linaclotide composition patent.[2][3]

A useful diligence structure is:

Patent layer	Key diligence question
Composition of matter	Has the core linaclotide protection expired or been extended?
Pharmaceutical composition	Does the claim require a particular excipient or ratio?
Dosage form	Is the claim directed to a capsule, powder, or other oral form?
Method of treatment	Does the claim cover the intended indication or patient population?
Pediatric administration	Does opening or sprinkling the capsule create a covered use?
Manufacturing	Does the process rely on protected synthesis or purification steps?
Packaging and stability	Are the moisture-control features independently claimed?

The Orange Book should be reviewed against the current FDA listing and the patent owner’s latest SEC filings before making a launch or licensing decision.[2][5]

Which companies are challenging Linzess patents?

Generic-drug companies have pursued linaclotide through ANDA filings and patent litigation. Publicly reported challengers have included Zydus and other generic manufacturers involved in Linzess patent disputes or settlement activity.[2][3]

Paragraph IV risk

A Paragraph IV certification alleges that an Orange Book-listed patent is invalid, unenforceable, or not infringed. For Linzess, the commercial impact of a Paragraph IV filing depends on:

• The specific strength being challenged
• Whether the challenge targets composition, formulation, or use claims
• The filing date and 30-month stay
• The outcome of district-court litigation
• Any settlement restrictions
• Whether the generic applicant receives tentative or final approval

A Paragraph IV case can accelerate supplier qualification because the ANDA sponsor must finalize commercial formulation, analytical controls, packaging, and manufacturing capacity before litigation concludes.

What generic entry risks exist for Linzess?

Linzess generic entry is likely to produce different effects across strengths and indications.

Generic capsule competition

The 72-mcg capsule is strategically important because it is the pediatric dose and a lower-dose adult option. Generic manufacturers must show reliable content uniformity at the lowest strength. This can make the 72-mcg product more technically demanding than a simple proportional scale-down from the 145-mcg or 290-mcg capsules.

The 145-mcg and 290-mcg strengths may be more attractive for adult chronic-use volume. Manufacturers may seek a common excipient platform across all three strengths to reduce manufacturing complexity, but the low-dose strength may require separate blending or filling controls.

Authorized generic risk

An authorized generic supplied by the brand owner or its commercial partner can enter with a known formulation, established manufacturing history, and existing supply chain. That can reduce the addressable market for independent excipient innovation, although it can also create secondary demand for capsule shells, packaging, and contract manufacturing.

Pediatric substitution risk

Generic substitution may be narrower in pediatric practice if caregivers and prescribers value the established sprinkle instructions and administration behavior. A generic that matches the labeled administration method and demonstrates equivalent handling can reduce this differentiation.

What commercial opportunities exist for Linzess excipient suppliers?

The largest opportunities are adjacent to the active pharmaceutical ingredient rather than in replacement of the branded excipient system.

1. Low-dose carrier systems

Suppliers can offer microcrystalline cellulose or alternative diluent systems optimized for:

• Low-dose peptide distribution
• Reduced segregation
• Improved capsule-fill weight consistency
• Low residual moisture
• High-speed filling

A supplier with validated blend-uniformity performance can gain earlier access to generic development programs.

2. Capsule-shell alternatives

Hypromellose capsules may appeal to manufacturers seeking vegetarian, moisture-controlled, or supply-diversified options. Gelatin remains commercially relevant because of established use and manufacturing familiarity.

Potential differentiation includes:

• Controlled moisture transmission
• Reduced brittleness
• Improved machine performance
• Color consistency
• Compatibility with low-moisture peptide formulations

Any shell change requires comparative stability and dissolution work.

3. Pediatric sprinkle excipients

A pediatric-oriented excipient platform could improve:

• Powder dispersion on applesauce
• Dose recovery from the capsule and food
• Reduced clumping
• Reduced adherence to spoons or cups
• Neutral taste and mouthfeel

The supplier must avoid creating a new administration burden. A formulation that requires special preparation may be commercially inferior to the current capsule-opening instructions.

4. Moisture-protective packaging

Packaging suppliers can target Linzess generics with high-barrier blister systems, desiccants, and low-moisture bottle configurations. The strongest commercial proposition combines packaging selection with stability modeling and validated shelf-life data.

5. Contract development and manufacturing

Generic sponsors may outsource:

• Excipient screening
• Design-of-experiments studies
• Blend-uniformity development
• Capsule-filling process development
• Stability programs
• Pediatric administration studies
• Analytical method transfer

This creates opportunities for CDMOs with low-dose peptide and oral-solid-dose experience.

How strong is the Linzess patent estate?

The estate is commercially meaningful but layered. Core linaclotide protection is easier to assess than later formulation, use, and pediatric barriers. The strongest barriers are those that cover the active molecule or a formulation necessary to achieve the marketed product’s performance. Narrow claims that cover only a specific excipient combination may be easier for a generic manufacturer to design around.

Patent strength should be assessed against five factors:

1. Claim breadth.
2. Remaining patent term.
3. Orange Book listing status.
4. Litigation history and settlement terms.
5. Availability of clinically and commercially acceptable design-arounds.

For excipient companies, the key issue is whether a proposed material is necessary to practice a patented formulation claim. A supplier can reduce risk by offering multiple grades and independent formulation routes rather than tying its commercial strategy to a single patented composition.

How does Linzess compare with competing constipation drugs?

Linzess competes with Amitiza, Trulance, Relistor, Motegrity, over-the-counter polyethylene glycol products, stimulant laxatives, and newer prescription constipation therapies. Its excipient strategy differs from small-molecule tablets because linaclotide is a microgram-dose peptide delivered locally in the intestine.

Product	Active ingredient	Formulation implication
Linzess	Linaclotide	Low-dose peptide capsule; moisture and content uniformity are central
Trulance	Plecanatide	Similar GC-C agonist category; competing peptide formulation demands
Amitiza	Lubiprostone	Small-molecule softgel formulation and oil-based excipient considerations
Motegrity	Prucalopride	Conventional small-molecule tablet platform
MiraLAX	Polyethylene glycol 3350	Powder-for-solution product with different excipient and packaging economics

Linzess and Trulance are the closest technical comparison because both are guanylate cyclase-C agonists. A supplier with peptide-compatible excipient and moisture-control technology can potentially address both products, although formulation claims and manufacturing processes differ.

What revenue exposure does Linzess create for the supply chain?

Linzess is a major commercial product for Ironwood and AbbVie. U.S. sales have reached the billion-dollar range annually, creating substantial value for active-ingredient, capsule, excipient, packaging, and contract-manufacturing suppliers.[2][3]

Revenue exposure is concentrated in:

• Linaclotide drug substance
• Specialty excipients used for low-dose blending
• Capsule shells
• Moisture-protective packaging
• Stability and analytical services
• Generic development programs
• Pediatric administration support

The largest near-term opportunity is not necessarily a new excipient patent. It is qualification as a reliable second source before generic competition expands.

What litigation and settlement agreements affect Linzess?

Linzess patent litigation has involved ANDA filers challenging Orange Book-listed patents. Settlements may permit a generic launch before the final expiry of every listed patent, subject to agreed dates and conditions. The economic impact depends on whether the settlement allows one entrant, multiple entrants, an authorized generic, or a later unrestricted launch.[2][3]

Settlement terms can affect excipient demand in two ways:

• A delayed launch creates a preparation period in which suppliers qualify materials and validate processes.
• An early or staggered launch can create immediate demand for commercial-scale excipient supply and packaging.

Patent litigation status should be checked against current federal court dockets, FDA approval records, Orange Book listings, and the latest Ironwood and AbbVie disclosures.[2][5]

What geographic markets offer Linzess excipient opportunities?

The U.S. is the largest commercial market and the primary focus for Orange Book and ANDA activity. International markets create separate opportunities because patent terms, regulatory pathways, product names, and formulation requirements differ.

Priority regions include:

• United States: ANDA competition, Orange Book patents, pediatric labeling, and high sales exposure.
• Europe: national and centralized regulatory requirements, with country-specific reimbursement.
• Japan: local regulatory and manufacturing expectations.
• Canada and Australia: smaller markets with separate generic approval pathways.
• Emerging markets: price-sensitive demand and greater emphasis on robust, low-cost formulations.

A global excipient supplier benefits from compendial compliance across jurisdictions, dual manufacturing sites, and documentation that supports FDA, EMA, PMDA, and other regulatory submissions.

Key Takeaways

• Linzess is a microgram-dose peptide capsule, making content uniformity, moisture control, and powder handling central excipient issues.
• The FDA-approved strengths are 72 mcg, 145 mcg, and 290 mcg.
• The 72-mcg pediatric strength creates the most important opportunity for sprinkle-performance, dose-recovery, and caregiver-use improvements.
• Commercial opportunities include low-dose carrier systems, capsule shells, high-barrier packaging, stability services, and generic-development support.
• Linzess patent protection includes composition, formulation, method-of-use, and manufacturing-related layers.
• Paragraph IV activity and settlement agreements can accelerate demand for generic-ready excipient systems before market entry.
• The strongest supplier position is based on validated performance, regulatory documentation, and reliable commercial supply rather than material novelty alone.
• Linzess and Trulance are the closest formulation competitors because both are peptide GC-C agonists.

FAQs

Can a generic Linzess manufacturer change the inactive ingredients?

Yes. An ANDA applicant may use different inactive ingredients if the product meets applicable quality, performance, stability, labeling, and bioequivalence requirements. A formulation change can increase development and regulatory work, particularly for a low-dose peptide.

Which Linzess strength has the greatest formulation risk?

The 72-mcg strength generally presents the greatest content-uniformity risk because the active load is smallest. It is also the pediatric strength, which increases the importance of capsule-opening and sprinkle administration performance.

Are excipients in Linzess themselves patentable?

An excipient can be part of a patent claim when the claim covers a specific formulation, ratio, performance property, or use. A commonly used excipient is not automatically patent-protected merely because it appears in the branded product.

Can a new Linzess excipient formulation obtain FDA approval as a 505(b)(2) product?

A 505(b)(2) pathway may be relevant to a product that relies partly on FDA findings for an approved drug but introduces a clinically meaningful formulation or delivery change. A conventional generic capsule more commonly proceeds through the ANDA pathway.

What is the most attractive licensing opportunity around Linzess?

The strongest licensing opportunities are likely to involve pediatric administration technology, moisture-protective packaging, low-dose peptide blending, and formulation platforms that can support both Linzess and related peptide gastrointestinal products.

References

1. U.S. Food and Drug Administration. (2023). Linzess (linaclotide) capsules prescribing information. AbbVie Inc. and Ironwood Pharmaceuticals, Inc.

2. Ironwood Pharmaceuticals, Inc. (2023). Form 10-K annual report. U.S. Securities and Exchange Commission.

3. AbbVie Inc. (2023). Form 10-K annual report. U.S. Securities and Exchange Commission.

4. U.S. Food and Drug Administration. (2023, June 12). FDA approves treatment for pediatric functional constipation. FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.